This article is more than 5 years old. Information may no longer be current.
Vosevi safely treats HCV in patients with prior treatment failure
Click Here to Manage Email Alerts
Treatment with Vosevi, a combination of sofosbuvir, velpatasvir and voxilaprevir, was an effective and safe therapy for patients with prior direct-acting antiviral treatment failure, according to findings published in the Journal of Hepatology.
“The aim of this study was to evaluate in the real-world setting the efficacy and safety of the fixed-dose combination of sofosbuvir, velpatasvir and voxilaprevir for 12 weeks in patients with chronic hepatitis C of any genotype and with different degrees of liver fibrosis who had previously failed oral DAA therapy,” Jordi Llaneras, MD, of Hospital Universitari Vall d'Hebron, and colleagues wrote.
Researchers conducted the study across 28 hospitals in Spain. The study comprised 137 patients (75% men; median age, 56 years), with 34% having compensated liver cirrhosis and 4% with HIV coinfection. Each patient received a fixed-dose oral tablet containing 400 mg of sofosbuvir, 100 mg of velpatasvir, and 100 mg of voxilaprevir (Vosevi or SOF/VEL/VOX, Gilead Sciences) without ribavirin once daily over the course of 12 weeks.
The data revealed that 95% of patients reached SVR12. However, SVR was lower in patients with cirrhosis (89%; P = .05) and those with genotype 3 infection (80%; P < .001). The most common adverse events included headaches (36%), followed by asthenia (32%), diarrhea (12%) and nausea (12%).
“The real-world data obtained here support the notion that SOF/VEL/VOX for 12 weeks is a safe, effective regimen for retreatment of HCV patients previously failing DAA therapy,” Llaneras and colleagues wrote. “However, lower SVR12 rates were documented in the subgroup of patients with HCV genotype 3 and liver cirrhosis who had been previously treated with sofosbuvir plus daclatasvir.”– by Alexandria Brooks
Disclosures: Llaneras reports no relevant financial disclosures. Please see the full study for all the other authors’ relevant financial disclosures.